Aptinyx (NASDAQ:APTX) Releases Earnings Results, Beats Expectations By $0.02 EPS

Aptinyx (NASDAQ:APTXGet Rating) issued its earnings results on Thursday. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02, Fidelity Earnings reports. During the same period last year, the company earned ($0.22) earnings per share.

Shares of Aptinyx stock opened at $0.70 on Friday. The business has a fifty day simple moving average of $1.78 and a 200-day simple moving average of $2.43. Aptinyx has a fifty-two week low of $0.57 and a fifty-two week high of $4.73. The firm has a market cap of $47.40 million, a price-to-earnings ratio of -0.59 and a beta of 1.46. The company has a quick ratio of 20.18, a current ratio of 20.18 and a debt-to-equity ratio of 0.15.

A number of institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its position in shares of Aptinyx by 244.5% during the 2nd quarter. Royal Bank of Canada now owns 9,288 shares of the company’s stock valued at $26,000 after purchasing an additional 6,592 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Aptinyx by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 123,937 shares of the company’s stock worth $331,000 after buying an additional 6,133 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new position in Aptinyx in the fourth quarter worth approximately $54,000. Millennium Management LLC increased its holdings in shares of Aptinyx by 19.7% in the fourth quarter. Millennium Management LLC now owns 1,246,945 shares of the company’s stock valued at $3,329,000 after buying an additional 205,553 shares in the last quarter. Finally, Susquehanna International Group LLP lifted its position in shares of Aptinyx by 56.8% during the 4th quarter. Susquehanna International Group LLP now owns 243,275 shares of the company’s stock valued at $650,000 after acquiring an additional 88,141 shares during the last quarter. Hedge funds and other institutional investors own 55.97% of the company’s stock.

Several brokerages have weighed in on APTX. BMO Capital Markets dropped their target price on Aptinyx from $12.00 to $6.00 in a research report on Friday, April 8th. William Blair downgraded shares of Aptinyx from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 7th. Cantor Fitzgerald dropped their price target on shares of Aptinyx from $11.00 to $5.00 and set an “overweight” rating on the stock in a research note on Friday, April 8th. Truist Financial reduced their price objective on Aptinyx from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, April 8th. Finally, SVB Leerink lowered their target price on Aptinyx from $10.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $3.88.

About Aptinyx (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

Read More

Earnings History for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.